R&D News | pharmaphorum

News

Roche's Parkinson's hope fails second clinical trial

Roche and Prothena's alpha-synuclein-targeting prasinezumab for Parkinson's fails again, leaving them sifting through the data for efficacy signals.

News

Ottimo Pharma chief executive David Epstein

Ottimo raises $140m for its PD-1/VEGF cancer drug

Ottimo raises $140m for PD-1 and VEGF-targeting jankistomig, which the startup says is differentiated from bispecific antibodies in the class.

News

MSD makes its obesity move with $2bn Hansoh deal

MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.

News

Novo Holdings leads $100m round for novel painkiller biotech

SiteOne Therapeutics has completed a $100 million third-round financing that will support clinical trials of its non-opioid painkiller.

News

Sensorion encouraged by deafness gene therapy data

Sensorion's gene therapy for otoferlin-related hearing loss has shown early signs of improving hearing in two toddlers in a phase 1/2 trial.

News

Teva, Sanofi score well with anti-TL1A drug in IBD test

Phase 2b results with Sanofi and Teva's duvakitug are exciting and warrant a swift move to phase 3 in inflammatory bowel disease, say the companies.

Roche's Parkinson's hope fails second clinical trial

Ottimo raises $140m for its PD-1/VEGF cancer drug

MSD makes its obesity move with $2bn Hansoh deal

Novo Holdings leads $100m round for novel painkiller biotech

Sensorion encouraged by deafness gene therapy data

Teva, Sanofi score well with anti-TL1A drug in IBD test

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks